ABSTRACT
BACKGROUND: We observed a syndrome of intermittent fevers, early-onset lacunar strokes and other neurovascular manifestations, livedoid rash, hepatosplenomegaly, and systemic vasculopathy in three unrelated patients. We suspected a genetic cause because the disorder presented in early childhood. METHODS: We performed whole-exome sequencing in the initial three patients and their unaffected parents and candidate-gene sequencing in three patients with a similar phenotype, as well as two young siblings with polyarteritis nodosa and one patient with small-vessel vasculitis. Enzyme assays, immunoblotting, immunohistochemical testing, flow cytometry, and cytokine profiling were performed on samples from the patients. To study protein function, we used morpholino-mediated knockdowns in zebrafish and short hairpin RNA knockdowns in U937 cells cultured with human dermal endothelial cells. RESULTS: All nine patients carried recessively inherited mutations in CECR1 (cat eye syndrome chromosome region, candidate 1), encoding adenosine deaminase 2 (ADA2), that were predicted to be deleterious; these mutations were rare or absent in healthy controls. Six patients were compound heterozygous for eight CECR1 mutations, whereas the three patients with polyarteritis nodosa or small-vessel vasculitis were homozygous for the p.Gly47Arg mutation. Patients had a marked reduction in the levels of ADA2 and ADA2-specific enzyme activity in the blood. Skin, liver, and brain biopsies revealed vasculopathic changes characterized by compromised endothelial integrity, endothelial cellular activation, and inflammation. Knockdown of a zebrafish ADA2 homologue caused intracranial hemorrhages and neutropenia - phenotypes that were prevented by coinjection with nonmutated (but not with mutated) human CECR1. Monocytes from patients induced damage in cocultured endothelial-cell layers. CONCLUSIONS: Loss-of-function mutations in CECR1 were associated with a spectrum of vascular and inflammatory phenotypes, ranging from early-onset recurrent stroke to systemic vasculopathy or vasculitis. (Funded by the National Institutes of Health Intramural Research Programs and others.).
Subject(s)
Adenosine Deaminase/deficiency , Adenosine Deaminase/genetics , Intercellular Signaling Peptides and Proteins/deficiency , Intercellular Signaling Peptides and Proteins/genetics , Mutation , Stroke/genetics , Vascular Diseases/genetics , Age of Onset , Animals , Disease Models, Animal , Endothelium, Vascular/pathology , Female , Fever/genetics , Humans , Male , Pedigree , Polyarteritis Nodosa/genetics , Sequence Analysis, DNA , Skin/pathology , Vasculitis/genetics , Vasculitis/pathology , ZebrafishABSTRACT
PURPOSE OF REVIEW: A new autoinflammatory disease, deficiency of adenosine deaminase 2 (DADA2), caused by mutations in the CECR1 gene, was first reported in 2014. This review aims to update progress in defining, treating, and understanding this multi-faceted disorder. RECENT FINDINGS: DADA2 was first described in patients with systemic inflammation, mild immune deficiency, and vasculopathy manifested as recurrent stroke or polyarteritis nodosa (PAN). More than 125 patients have now been reported, and the phenotype has expanded to include children and adults presenting primarily with pure red cell aplasia (PRCA), or with antibody deficiency. Age of onset and clinical severity vary widely, even among related patients, and are not clearly related to CECR1 genotype. Inflammatory features often respond to anti-TNF agents, but marrow failure and severe immune deficiency may require hematopoietic stem cell transplantation. ADA2 is expressed and secreted by monocytes and macrophages, but its biological function and the pathogenesis of DADA2 are uncertain and will remain an important area of research. Pre-clinical investigation of ADA2 replacement therapy and CECR1-directed gene therapy are warranted, but complicated by the absence of a suitable animal model.
Subject(s)
Adenosine Deaminase/genetics , Genetic Predisposition to Disease , Intercellular Signaling Peptides and Proteins/genetics , Polyarteritis Nodosa/genetics , Rheumatic Diseases/genetics , Humans , Mutation , PhenotypeABSTRACT
Adenosine deaminase 2 deficiency is an autoinflammatory disease, characterized by various forms of vasculitis. We describe 5 patients with adenosine deaminase 2 deficiency with various hematologic manifestations, including pure red cell aplasia, with no evidence for vasculitis.
Subject(s)
Adenosine Deaminase/deficiency , Intercellular Signaling Peptides and Proteins/deficiency , Adenosine Deaminase/genetics , Child , Child, Preschool , Female , Humans , Infant , Intercellular Signaling Peptides and Proteins/genetics , Male , Metabolism, Inborn Errors/diagnosis , Metabolism, Inborn Errors/genetics , PhenotypeSubject(s)
Adenosine Deaminase/deficiency , Agammaglobulinemia/genetics , Intercellular Signaling Peptides and Proteins/deficiency , Severe Combined Immunodeficiency/genetics , Adenosine Deaminase/blood , Adenosine Deaminase/genetics , Agammaglobulinemia/blood , Child, Preschool , Female , Glycosylation , Humans , Intercellular Signaling Peptides and Proteins/blood , Intercellular Signaling Peptides and Proteins/genetics , Mutation , Severe Combined Immunodeficiency/bloodABSTRACT
A high plasma urate concentration (PUA), related to loss of urate oxidase in evolution, is postulated to protect humans from oxidative injury. This hypothesis has broad clinical relevance, but support rests largely on in vitro data and epidemiologic associations. Pegloticase therapy generates H(2)O(2) while depleting urate, offering an in vivo test of the antioxidant hypothesis. We show that erythrocytes can efficiently eliminate H(2)O(2) derived from urate oxidation to prevent cell injury in vitro; during therapy, disulfide-linked peroxiredoxin 2 dimer did not accumulate in red blood cells, indicating that their peroxidase capacity was not exceeded. To assess oxidative stress, we monitored F2-Isoprostanes (F2-IsoPs) and protein carbonyls (PC), products of arachidonic acid and protein oxidation, in plasma of 26 refractory gout patients receiving up to five infusions of pegloticase at 3-wk intervals. At baseline, PUA was markedly elevated in all patients, and plasma F2-IsoP concentration was elevated in most. Pegloticase infusion rapidly lowered mean PUA to < or = 1 mg/dL in all patients, and PUA remained low in 16 of 21 patients who completed treatment. F2-IsoP levels did not correlate with PUA and did not increase during 15 wk of sustained urate depletion. There also was no significant change in the levels of plasma PC. Because refractory gout is associated with high oxidative stress in spite of high PUA, and profoundly depleting uric acid did not increase lipid or protein oxidation, we conclude that urate is not a major factor controlling oxidative stress in vivo.
Subject(s)
Antioxidants/metabolism , Gout/drug therapy , Urate Oxidase/administration & dosage , Uric Acid/metabolism , Cells, Cultured , Erythrocytes/cytology , Erythrocytes/drug effects , Erythrocytes/metabolism , F2-Isoprostanes/metabolism , Gout/metabolism , Humans , Hydrogen Peroxide/metabolism , Oxidation-Reduction , Oxidative Stress , Polyethylene Glycols , Proteins/metabolism , Urate Oxidase/therapeutic use , Uric Acid/bloodSubject(s)
Adenosine Deaminase/deficiency , Agammaglobulinemia/diagnosis , Agammaglobulinemia/therapy , GATA2 Transcription Factor/deficiency , Hematopoietic Stem Cell Transplantation , Intercellular Signaling Peptides and Proteins/deficiency , Severe Combined Immunodeficiency/diagnosis , Severe Combined Immunodeficiency/therapy , Adenosine Deaminase/genetics , Adolescent , Adult , Agammaglobulinemia/genetics , Child , Child, Preschool , Codon, Nonsense , Diagnostic Errors , Female , Humans , Intercellular Signaling Peptides and Proteins/genetics , Male , Severe Combined Immunodeficiency/genetics , Transplantation, Haploidentical , Exome Sequencing , Young AdultSubject(s)
Anticoagulants/adverse effects , Aptamers, Nucleotide/adverse effects , Drug Hypersensitivity/immunology , Immunoglobulin G/immunology , Polyethylene Glycols , Anticoagulants/immunology , Aptamers, Nucleotide/immunology , Drug Hypersensitivity/diagnosis , Enzyme-Linked Immunosorbent Assay , Follow-Up Studies , HumansSubject(s)
Adenosine Deaminase/deficiency , Agammaglobulinemia/therapy , Hematopoietic Stem Cell Transplantation , Intercellular Signaling Peptides and Proteins/deficiency , Severe Combined Immunodeficiency/therapy , Adenosine Deaminase/blood , Adenosine Deaminase/genetics , Adenosine Deaminase/immunology , Agammaglobulinemia/blood , Agammaglobulinemia/genetics , Agammaglobulinemia/immunology , Child, Preschool , Humans , Infant , Intercellular Signaling Peptides and Proteins/blood , Intercellular Signaling Peptides and Proteins/genetics , Interleukin-6/blood , Lymphocyte Count , Male , Mutation , Phenotype , Severe Combined Immunodeficiency/blood , Severe Combined Immunodeficiency/genetics , Severe Combined Immunodeficiency/immunologyABSTRACT
Biopharmaceuticals have become increasingly attractive therapeutic agents and are often PEGylated to enhance their pharmacokinetics and reduce their immunogenicity. However, recent human clinical trials have demonstrated that administration of PEGylated compounds can evoke anti-PEG antibodies. Considering the ubiquity of PEG in commercial products and the presence of pre-existing anti-PEG antibodies in patients in large clinical trials evaluating a PEG-modified aptamer, we investigated how anti-PEG antibodies effect the therapeutic activities of PEGylated RNA aptamers. We demonstrate that anti-PEG antibodies can directly bind to and inhibit anticoagulant aptamer function in vitro and in vivo. Moreover, in parallel studies we detected the presence of anti-PEG antibodies in nonhuman primates after a single administration of a PEGylated aptamer. Our results suggest that anti-PEG antibodies can limit the activity of PEGylated drugs and potentially compromise the activity of otherwise effective therapeutic agents.
Subject(s)
Antibodies/immunology , Anticoagulants/chemistry , Aptamers, Nucleotide/immunology , Polyethylene Glycols/chemistry , Animals , Antibodies/blood , Antigen-Antibody Reactions , Aptamers, Nucleotide/administration & dosage , Aptamers, Nucleotide/chemistry , Chlorides/toxicity , Disease Models, Animal , Factor IXa/metabolism , Female , Ferric Compounds/toxicity , Humans , Macaca mulatta , Mice , Mice, Inbred C57BL , Partial Thromboplastin Time , Thrombosis/chemically induced , Thrombosis/drug therapy , Thrombosis/pathologyABSTRACT
The delivery of therapeutic peptides and proteins is often challenged by a short half-life, and thus the need for frequent injections that limit efficacy, reduce patient compliance and increase treatment cost. Here, we demonstrate that a single subcutaneous injection of site-specific (C-terminal) conjugates of exendin-4 (exendin) - a therapeutic peptide that is clinically used to treat type 2 diabetes - and poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA) with precisely controlled molecular weights lowered blood glucose for up to 120 h in fed mice. Most notably, we show that an exendin-C-POEGMA conjugate with an average of 9 side-chain ethylene glycol (EG) repeats exhibits significantly lower reactivity towards patient-derived anti-poly(ethylene glycol) (PEG) antibodies than two FDA-approved PEGylated drugs, and that reducing the side-chain length to 3 EG repeats completely eliminates PEG antigenicity without compromising in vivo efficacy. Our findings establish the site-specific conjugation of POEGMA as a next-generation PEGylation technology for improving the pharmacological performance of traditional PEGylated drugs, whose safety and efficacy are hindered by pre-existing anti-PEG antibodies in patients.
ABSTRACT
INTRODUCTION: Pegloticase, a PEGylated recombinant porcine uricase, is approved for treating refractory gout at a dose of 8 mg intravenous (IV) every 2 weeks. However, during phase 1 testing, pharmacokinetics supported less frequent dosing. Also, single doses of pegloticase unexpectedly induced antibodies (Ab) that bound to polyethylene glycol (PEG). We have conducted a phase 2 trial to evaluate every 3-week dosing, and to further define the Ab response to pegloticase. Organ transplant recipients were included, as they are prone to severe gout that is difficult to manage, and because treatment to prevent graft rejection might influence the immune response to pegloticase. METHODS: Plasma uricase activity (pUox), urate concentration (pUA), and clinical response were monitored during up to 5 infusions in 30 patients, including 7 organ transplant recipients. Depending on whether pUA <6 mg/dL was achieved and maintained, patients were classified as non (NR), persistent (PR), or transient (TR) responders. Ab to pegloticase and 10 kDa mPEG were monitored by enzyme linked immunosorbent assay and specificity was further defined. RESULTS: We observed 17 PR, 12 TR, and 1 NR; 21 patients (16 PR, 5 TR) received all 5 infusions. Over the 15-week trial, pUA in PR averaged 1.0 ± 0.4 mg/dL; T½ for pUox was approximately 13 days, and area under the curve after dose 5 was approximately 30% higher than after dose 1. PR showed clinical benefit and in some, tophi resolved. In 11 of 12 TR, pUox fell rapidly and hyperuricemia recurred before dose 2. In all TR and NR, loss of response to pegloticase was accompanied by Ab to PEG, which was pre-existing in half of those who had no prior exposure to pegloticase. No PR, and 1 one out of 7 organ transplant recipients, had a sustained Ab response to pegloticase. CONCLUSIONS: Every 3-week dosing is effective and may enhance the utility of pegloticase for treating refractory gout. Ab to PEG, which were pre-existing or induced by treatment, caused rapid loss of efficacy and increased the risk of infusion reactions. Organ transplant recipients can benefit from pegloticase, and may be less prone than non-recipients to developing anti-PEG Ab. Investigation of immunosuppressive strategies to minimize anti-PEG Ab is warranted. TRIAL REGISTRATION: ClincalTrials.gov identifier: NCT00111657.
Subject(s)
Gout Suppressants/administration & dosage , Gout Suppressants/immunology , Gout/drug therapy , Polyethylene Glycols/administration & dosage , Urate Oxidase/administration & dosage , Urate Oxidase/immunology , Adult , Aged , Aged, 80 and over , Antibodies/blood , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Polyethylene Glycols/pharmacokinetics , Transplant Recipients , Treatment Outcome , Urate Oxidase/pharmacokineticsABSTRACT
OBJECTIVE: To evaluate the efficacy, immunogenicity, and tolerability of intravenous (IV) PEGylated recombinant mammalian urate oxidase (PEG-uricase) for the treatment of severe gout. METHODS: Single infusions of PEG-uricase (at doses ranging from 0.5 mg to 12 mg) were administered to 24 patients (6 cohorts of 4 patients each) in a phase I clinical trial. Plasma uricase activity (pUox), the plasma urate concentration (pUAc), and the uric acid-to-creatinine ratio (UAc:Cr) in urine were monitored for 21 days after dosing. Adverse events and the IgG antibody response to PEG-uricase were followed up for 35 days. RESULTS: All patients completed the trial. Maximum pUox was linearly related to the IV dose of PEG-uricase, the area under the curve (AUC) value increased linearly (up to a dose of 8 mg), and the pUox half-life was 6.4-13.8 days. After doses of 4-12 mg, the pUAc fell within 24-72 hours, from a mean +/- SD value of 11.1 +/- 0.6 mg/dl to 1.0 +/- 0.5 mg/dl; the AUC value for the pUAc was equivalent to maintaining the pUAc at 1.2-4.7 mg/dl for 21 days postinfusion. The UAc:Cr ratio in urine fell in parallel with the pUAc. IgG antibodies to PEG-uricase, mostly IgG2 and specific for PEG, developed in 9 patients, who had more rapid enzyme clearance but no allergic reactions. All adverse events were mild to moderate, with gout flares being most common. CONCLUSION: The bioavailability, efficacy, and tolerability of IV PEG-uricase were greater than the bioavailability, efficacy, and tolerability observed in a previous phase I trial of subcutaneous PEG-uricase. Infusing 4-12 mg of PEG-uricase every 2-4 weeks should maintain the pUAc well below the therapeutic target of 6 mg/dl and greatly reduce renal uric acid excretion. This treatment could be effective in depleting expanded tissue urate stores in patients with chronic or tophaceous gout.
Subject(s)
Gout Suppressants/administration & dosage , Gout Suppressants/pharmacokinetics , Gout/drug therapy , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/pharmacokinetics , Urate Oxidase/administration & dosage , Urate Oxidase/pharmacokinetics , Adult , Aged , Antibodies/immunology , Antibodies/metabolism , Creatinine/urine , Dose-Response Relationship, Drug , Female , Gout Suppressants/adverse effects , Gout Suppressants/immunology , Humans , Infusions, Intravenous , Male , Middle Aged , Polyethylene Glycols/adverse effects , Urate Oxidase/adverse effects , Urate Oxidase/immunology , Uric Acid/urineABSTRACT
PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single subcutaneous injections of PEG-uricase (4 to 24 mg) were administered to 13 such subjects (11 had tophaceous gout), whose plasma uric acid concentration (pUAc) was 11.3 +/- 2.1 mg/dl (mean +/- SD). By day seven after injection of PEG-uricase, pUAc had declined by an average of 7.9 mg/dl and had normalized in 11 subjects, whose mean pUAc decreased to 2.8 +/- 2.2 mg/dl. At doses of 8, 12, and 24 mg, the mean pUAc at 21 days after injection remained no more than 6 mg/dl. In eight subjects, plasma uricase activity was still measurable at 21 days after injection (half-life 10.5 to 19.9 days). In the other five subjects, plasma uricase activity could not be detected beyond ten days after injection; this was associated with the appearance of relatively low-titer IgM and IgG antibodies against PEG-uricase. Unexpectedly, these antibodies were directed against PEG itself rather than the uricase protein. Three PEG antibody-positive subjects had injection-site reactions at 8 to 9 days after injection. Gout flares in six subjects were the only other significant adverse reactions, and PEG-uricase was otherwise well tolerated. A prolonged circulating life and the ability to normalize plasma uric acid in markedly hyperuricemic subjects suggest that PEG-uricase could be effective in depleting expanded tissue stores of uric acid in subjects with chronic or tophaceous gout. The development of anti-PEG antibodies, which may limit efficacy in some patients, is contrary to the general assumption that PEG is non-immunogenic. PEG immunogenicity deserves further investigation, because it has potential implications for other PEGylated therapeutic agents in clinical use.